Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases

This publication has 18 references indexed in Scilit:

• Diagnosis of Pancreatic Carcinoma
  Pancreas, 1992
• The Use and Potential of Serum Tumour Markers, New and Old
  Drugs, 1989
• Serum tissue polypeptide antigen in pancreatic cancer and other gastrointestinal diseases.
  Journal of Clinical Pathology, 1989
• Elevated serum levels of tumor marker CA19-9 in acute cholangitis
  Digestive Diseases and Sciences, 1988
• Combined Determination of Serum CA 19-9 and Tissue Polypeptide Antigen: Why No Improvement in Pancreatic Cancer Diagnosis
  Oncology, 1988
• Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
  Gut, 1987
• Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor
  Cancer, 1985
• Immunological study of tissue polypeptide antigen (TPA)—demonstration of keratin-like sites and blood group antigen-like sites on TPA molecules
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1985
• Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
  Journal of Clinical Pathology, 1984
• Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA)
  Digestive Diseases and Sciences, 1983